Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MND-2119 Phase 3 Long-term Study in Hypertriglyceridemia
NCT04221217Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Epadel in hypertriglyceridemia (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Adverse Events at 52 weeks. Started Feb 2020; status: completed.
02
Drugs
Epadel
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT04221217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221217.